about us


We are an oncology company focused on the clinical development of novel therapies for cancer. Our lead programs include a potential best-in-class HDAC inhibitor, Pracinostat, a novel mitochondrial inhibitor, ME-344, and a PI3-kinase delta inhibitor, PWT143.
[ Read more ]

latest news

MEI Pharma Reports High Response Rates in Phase II Study of Pracinostat in Front Line Acute Myeloid Leukemia
[ June 10, 2014 ]

MEI Pharma to Present at Wells Fargo Healthcare Conference
[ June 9, 2014 ] [ Webcast ]

MEI Pharma Initiates Clinical Study of Mitochondrial Inhibitor ME-344 in Small Cell Lung and Ovarian Cancers
[ May 5, 2014 ]

MEI Pharma Identifies Potential Biomarker for Pracinostat in Bladder Cancer (AACR) [ April 7, 2014 ] [ Poster ]

Annual Review Cover
Click here for our 2013 Annual Review